Antibiotics Patents (Class 536/16.8)
-
Patent number: 8216592Abstract: The present invention relates to a small animal model useful in identifying novel therapies for treating pathogenic diseases. This flexible biotechnology tool is valuable for developing novel chemotherapeutics for a broad range of microbial pathogens.Type: GrantFiled: April 19, 2007Date of Patent: July 10, 2012Assignee: The Reed InstituteInventor: Jay L. Mellies
-
Patent number: 8198419Abstract: The present invention provides glycorandomaized structures and combinatorial methods for rapidly generating a diverse library of glycorandomized structures, comprising incubating one or more aglycons and a pool of NDP-sugars in the presence of a glycosyltransferase. The glycosyltransferase may be one that is associated with or involved in production of natural secondary metabolites, or one which is putatively associated with or involved in production of natural secondary metabolites. The glycosyltransferase may show significant flexibility with respect to its NDP-sugar donors and/or its aglycons. NDP-sugar donors may be commercially available, or may be produced by utilizing mutant or wild type nucleotidyltransferases significant flexibility with respect to their substrates.Type: GrantFiled: February 1, 2011Date of Patent: June 12, 2012Assignee: Wisconsin Alumni Research FoundationInventor: Jon Thorson
-
Publication number: 20120141590Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.Type: ApplicationFiled: September 30, 2011Publication date: June 7, 2012Inventors: Michael Malakhov, Fang Fang
-
Publication number: 20120135945Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: November 14, 2011Publication date: May 31, 2012Applicant: Achaogen, Inc.Inventors: Paola Dozzo, Adam Aaron Goldblum, James Bradley Aggen, Martin Sheringham Linsell
-
Publication number: 20120135946Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 or R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: November 14, 2011Publication date: May 31, 2012Applicant: Achaogen, Inc.Inventors: Adam Aaron Goldblum, Paola Dozzo, James Bradley Aggen, Martin Sheringham Linsell
-
Publication number: 20120122809Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein Q1 and Q2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: November 14, 2011Publication date: May 17, 2012Applicant: Achaogen, Inc.Inventors: Adam Aaron Goldblum, Paola Dozzo, Timothy Robert Kane, James Bradley Aggen, Martin Sheringham Linsell, Darin James Hildebrandt, Micah James Gliedt
-
Publication number: 20120058960Abstract: Compounds and methods for use in selectively inhibiting a lytic enzyme based on feedback inhibition are described. The conjugated compound serves as a substrate for a lytic enzyme. Cleavage of the conjugated compound by the lytic enzyme releases an inhibitor of the enzyme.Type: ApplicationFiled: August 31, 2011Publication date: March 8, 2012Applicant: University of Georgia Research Foundation, Inc.Inventors: Geert-Jan BOONS, Jun Guo
-
Publication number: 20120058148Abstract: Compounds that are adjuvants and immunoeffectors are described and claimed. The compounds augment antibody production in immunized animals as well as stimulate cytokine production and activate macrophages. Compositions and methods for using the compounds as adjuvants and immunoeffectors are also disclosed.Type: ApplicationFiled: May 24, 2011Publication date: March 8, 2012Applicant: Corixa CorporationInventors: David A. Johnson, David Persing
-
Publication number: 20120040431Abstract: The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells by, for example, a pre-targeting technique utilizing bispecific or multispecific antibodies or fragments, having at least one binding arm that recognizes the hapten and at least a second binding arm that binds specifically to a disease or pathogen associated antigen, such as a tumor associated antigen. Methods for synthesizing and using such therapeutic-loaded polymers and their conjugates are provided.Type: ApplicationFiled: September 27, 2011Publication date: February 16, 2012Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg, Chien-Hsing Chang
-
Publication number: 20120029167Abstract: A drug using the magnetic properties of a metal salen complex as represented by the following general formula in order to magnetize the intended drug by chemically binding the drug to a metal salen complex so that the drug can be delivered to the target diseased site. The drug can be delivered to the diseased site using the magnetic properties of the drug per se without using a carrier made of a magnetic substance as in the conventional methods.Type: ApplicationFiled: May 20, 2011Publication date: February 2, 2012Applicants: Yoshihiro Ishikawa, IHI CorporationInventors: Yoshihiro ISHIKAWA, Haruki Eguchi
-
Patent number: 8075902Abstract: New devices and methods for diagnosis and compositions and methods for treatment of cancers use combinations of antimicrobial agents and agents that can reverse dormancy and hibernation pathways. We unexpectedly found that surprisingly low doses of anti-hibernation compounds can substantially inhibit cancer cell growth in vitro and can successfully treat cancers, including metastatic cancer. We also unexpectedly found that antimicrobial agents and anti-HDS compounds together can increase the degree of inhibition of cancer cell growth in a synergistic fashion. We conclude that combination therapy with antimicrobial agents and anti-HDS compounds can be effective in treating human patients with cancer.Type: GrantFiled: January 2, 2008Date of Patent: December 13, 2011Inventor: Michael Powell
-
Publication number: 20110288041Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: April 7, 2011Publication date: November 24, 2011Applicant: Achaogen, Inc.Inventors: James Bradley Aggen, Martin Sheringham Linsell, Adam Aaron Goldblum, Darin James Hildebrandt, Timothy Robert Kane, Paola Dozzo, Micah James Gliedt, Heinz Ernst Moser
-
Patent number: 8058247Abstract: An antibacterial agent having high antibacterial activity against Mycobacterium avium subsp. paratuberculosis is provided. Specifically, the antibacterial agent of the present invention having high antibacterial activity against Mycobacterium avium subsp. paratuberculosis is a caprazamycin derivative represented, for example, by the following general formula (II): wherein Me is a methyl group; and R1 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, a cycloalkyl group having 5 to 12 carbon atoms, or a phenyl group substituted at the para-position with a straight chain alkyl group having 1 to 14 carbon atoms, a straight chain alkoxy group having 1 to 9 carbon atoms or a cycloalkyl group having 5 to 12 carbon atoms.Type: GrantFiled: February 11, 2009Date of Patent: November 15, 2011Assignees: Microbial Chemistry Research Foundation, Meiji Seika Kaisha, Ltd.Inventors: Yoshiaki Takahashi, Masayuki Igarashi
-
Publication number: 20110275586Abstract: Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Z1, Z2, Z3, Z4, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: March 9, 2011Publication date: November 10, 2011Applicant: Achaogen, Inc.Inventors: James Bradley Aggen, Martin Sheringham Linsell, Adam Aaron Goldblum, Darin James Hildebrandt, Timothy Robert Kane, Paola Dozzo, Micah James Gliedt, Stephen Hanessian, Alexandre Giguère, Justyna Grzyb, Juan Pablo Maianti
-
Publication number: 20110218168Abstract: Disclosed are methods of treating bacterial infections including those caused by multidrug resistant bacteria using polyamine efflux pump inhibiting compounds, including for example N-benzylated polyazaalkanes, N-benzylated polyaminoalkanes, or mixed N-benzylated poly(aza/amino)alkanes, optionally in combination with other drugs such as antibiotics, as well as pharmaceutical compositions thereof.Type: ApplicationFiled: September 29, 2010Publication date: September 8, 2011Applicant: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Michael N. Alekshun
-
Publication number: 20110136752Abstract: The invention relates generally to novel antibiotics and their analogs, to processes for the preparation of these novel antibiotics, to pharmaceutical compositions comprising the novel antibiotics; and to methods of using the novel antibiotics to treat or inhibit various disorders.Type: ApplicationFiled: December 6, 2010Publication date: June 9, 2011Applicant: NOVOBIOTIC PHARMACEUTICALS LLCInventors: Aaron PEOPLES, Lucy Losee LING, Kim LEWIS, Zhizhen ZHANG
-
Publication number: 20110118202Abstract: The dimerization of HIV RNA is a key step in the virus replication cycle. Based on RNA DIS crystal structures, a novel kind of compounds, dimeric or not, based on neamine was designed and synthesized. Biological studies showed that such compounds bind and interfere with the targeted RNA sequence, opening a new anti-HIV approach. The crystal structures and bio-chemical experiments showed that the DIS of HIV-1 genomic RNA is a target for new anti-HIV drugs and that those drugs could be derived from aminoglycosides. The results revealed that binding of aminoglycosides to the DIS is specific regarding both the aminoglycoside family and the RNA subtype.Type: ApplicationFiled: March 23, 2007Publication date: May 19, 2011Inventors: Patrick Pale, Jean-Marc Weibel, Anne Bodlenner, Roland Marquet, Jean-Cristophe Paillart, Philippe Dumas, Eric Ennifar, Philippe Walter
-
Patent number: 7935799Abstract: Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO.Type: GrantFiled: August 28, 2009Date of Patent: May 3, 2011Assignee: Cedars-Sinai Medical CenterInventors: Henry C. Lin, Mark Pimentel
-
Publication number: 20110098239Abstract: The present invention relates to a diaryl hepatonoid-based compound of formula (1) having viral inhibitory activity; its pharmaceutically acceptable salt; or a hydrate, a solvate or a prodrug of any of the foregoing, and a pharmaceutical composition comprising the same, and the use thereof therapeutic agents. The diaryl hepatonoid-based compounds according to present invention have an excellent effect of inhibiting viral activity, and thus will be useful as therapeutic agents against virus-related diseases.Type: ApplicationFiled: June 4, 2009Publication date: April 28, 2011Inventors: Jeong Chan Ra, Young Ho Kim, Hyuk Joon Kwon, Huu Tung Nguyen
-
Publication number: 20110003980Abstract: An oligo-aminosaccharide compound formed by binding 3 to 6 saccharides, such as 2,6-diamino-2,6-dideoxy-?-(1?4)-D-glucopyranose oligomers, or a salt thereof, which has high affinity to a double-stranded nucleic acid.Type: ApplicationFiled: March 9, 2010Publication date: January 6, 2011Applicant: The University of TokyoInventors: Takeshi Wada, Rintaro Iwata
-
Publication number: 20100292179Abstract: We describe the functional cloning and the use of a non-fungal inositol phosphoryceraminde synthase (IPC synthase) in a screening assay for the identification of agents that target and antagonize the activity of IPC synthase.Type: ApplicationFiled: January 19, 2007Publication date: November 18, 2010Applicant: The University of DurhamInventors: Paul William Denny, Ralph Thomas Schwarz, Hosam Shams-Eldin
-
Publication number: 20100286031Abstract: An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present at a concentration ranging from about 0.6 to about 0.9 of the water solubility limit, at 25° C. and 1.0 atmosphere, of the anti-gram-positive antibiotic or salt thereof. Other embodiments include unit doses, kits, and methods.Type: ApplicationFiled: September 28, 2006Publication date: November 11, 2010Inventors: Chatan K. Charan, Sarvajna Dwivedi
-
Publication number: 20100273726Abstract: This present provides kaempferol-3-(2-E,3-Z-di-p-coumaroyl)-rhamnoside, kaempferol-3-(2-Z-3-E-di-p-coumaroyl)-rhamnoside, and kaempferol-3-(2,3-di-Z-p-coumaroyl)-rhamnoside compounds useful as a new class of anti-bacterial agents. These compounds are extracted from Platanus occidentalis or Laurus nobilis. These compounds were found to exhibit anti-bacterial activity against methicillin resistant Staphylococcus aureus (MRSA).Type: ApplicationFiled: April 27, 2010Publication date: October 28, 2010Applicant: TRITON BIOPHARMAInventors: Mark T. Hamann, Mohamed A. Ibrahim
-
Patent number: 7759482Abstract: The present invention provides aminoglycosides and pharmaceutical compositions that include the aminoglycosides. The aminoglycosides are useful to treat or prevent infectious diseases (e.g., bacterial infections) in a mammal (e.g., human).Type: GrantFiled: May 2, 2007Date of Patent: July 20, 2010Assignee: Wayne State UniversityInventors: Jalal Haddad, Lakshmi Kotra, Shahriar Mobashery
-
Patent number: 7732582Abstract: A dicarboxylic acid compound obtainable by oxidative degradation of pradimicin antibiotics, which are antibiotics consisting of the benzonaphthacene skeleton, a D-amino acid side chain and a sugar chain, for the second saccharide residue of the sugar chain, and use thereof utilizing a specific microorganism binding property thereof are provided. The dicarboxylic acid compound has significantly improved water-solubility compared with the raw material antibiotics, whist maintaining the specific microorganism binding property.Type: GrantFiled: September 5, 2005Date of Patent: June 8, 2010Assignee: FUJIFILM CorporationInventors: Toshikazu Oki, Yasuhiro Igarashi, Tamotsu Furumai
-
Publication number: 20100086973Abstract: The present invention provides compounds characterized by the formula (I), where each of the substituent radicals is described in the specification. The invention also describes the use of said compounds in the treatment of various diseases, including: cancer or tumoral processes in general, Paget's disease, hypercalcaemia, hypercalciuria and neurological diseases (inter alia, Parkinson's, Alzheimer's, Huntington's).Type: ApplicationFiled: February 4, 2008Publication date: April 8, 2010Applicant: University of Kentucky Research FoundationInventors: Jürgen Rohr, Irfan Baig, José Antonio Salas Fernández, Alfredo Fernández Braña, Carmen Méndez Fernández, Mariá Pérez Solares
-
Patent number: 7683161Abstract: Spinetoram is selectively produced in excellent yields by hydrogenating a mixture of 3?-O-ethyl spinosyn J and 3?-O-ethyl spinosyn L in a water miscible organic solvent using hydrogen gas and a heterogeneous catalyst.Type: GrantFiled: November 2, 2007Date of Patent: March 23, 2010Assignee: Dow AgroSciences LLCInventors: David E. Podhorez, Gary A. Roth, David C. Molzahn, Timothy Adaway
-
Publication number: 20090312530Abstract: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.Type: ApplicationFiled: August 17, 2009Publication date: December 17, 2009Applicant: WyethInventors: Justin Keith Moran, Jianxin Gu
-
Patent number: 7626005Abstract: The present invention relates to novel inhibitors of aminoglycoside 6?-N-acetyltransferases, more specifically, AAC(6?)-li and AAC(6?)-ly, as well as compositions and uses thereof. Furthermore, the present invention relates to synthetic methodologies for preparing the inhibitors of aminoglycoside 6?-N-acetyltransferases.Type: GrantFiled: February 21, 2006Date of Patent: December 1, 2009Assignee: McGill UniversityInventors: Karine Auclair, Feng Gao, Xuxu Yan
-
Publication number: 20090288658Abstract: An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present at a concentration ranging from about 0.6 to about 0.9 of the water solubility limit, at 25° C. and 1.0 atmosphere, of the anti-gram-positive antibiotic or salt thereof. Other embodiments include unit doses, kits, and methods.Type: ApplicationFiled: December 22, 2008Publication date: November 26, 2009Applicant: Nektar TherapeuticsInventors: Chatan Charan, Sarvajna Dwivedi
-
Patent number: 7605240Abstract: Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO.Type: GrantFiled: August 14, 2007Date of Patent: October 20, 2009Assignee: Cedara-Sinai Medical CenterInventors: Henry C. Lin, Mark Pimentel
-
Patent number: 7592023Abstract: The present invention relates to media containing purified antimicrobial polypeptides, such as defensins, and/or cell surface receptor binding proteins. The media may also contain buffers, macromolecular oncotic agents, energy sources, impermeant anions, ATP substrates. The media find use for the storage and preservation of internal organs prior to transplant.Type: GrantFiled: September 9, 2003Date of Patent: September 22, 2009Assignee: Trophic Solutions LLCInventors: Christopher J. Murphy, Jonathan F. McAnulty, Ted W. Reid
-
Publication number: 20090209744Abstract: An antibacterial agent having high antibacterial activity against Mycobacterium avium subsp. paratuberculosis is provided. Specifically, the antibacterial agent of the present invention having high antibacterial activity against Mycobacterium avium subsp. paratuberculosis is a caprazamycin derivative represented, for example, by the following general formula (II): wherein Me is a methyl group; and R1 is a straight or substantially straight chain alkyl group having 5 to 21 carbon atoms, a straight or substantially straight chain alkenyl group having 5 to 21 carbon atoms, a cycloalkyl group having 5 to 12 carbon atoms, or a phenyl group substituted at the para-position with a straight chain alkyl group having 1 to 14 carbon atoms, a straight chain alkoxy group having 1 to 9 carbon atoms or a cycloalkyl group having 5 to 12 carbon atoms.Type: ApplicationFiled: February 11, 2009Publication date: August 20, 2009Inventors: Yoshiaki Takahashi, Masayuki Igarashi
-
Publication number: 20090069220Abstract: A conjugate of formula: V—(Y)a-Z-T??(I), T-X—B—(Y)a-Z-T???(II), V—(Y)a-Z-(Y?)a—V???(III), T-X—B—(Y)a-Z-(Y?)a—X?—B?-T???(IV), V—(Y)a-Z-(Y?)a—X—B-T??(V), V—(Y)a-Z-X—B-Z?-(Y?)a—(V?)b??(VI), or (W)a—(Y)b-[(Z)c-(Y?)d—(X—B)e—(Y?)f-(Z?)g]h-(Y??)i—(W?)j??(VII), in which W and W? are independently a DNA intercalator or terminal subunit, V and V? are independently a DNA intercalator, X and X? are independently a DNA alkylator, B and B? are the same or different and each is a heteroaromatic residue that is attached to the N-terminus of an alkylator subunit (X or X?), Y, Y?, Y? and Y?? are independently a linker, T and T? are independently terminal subunits, Z and Z? are independently a polyamide group that binds to the minor groove of DNA, a, b, c, d, f, g, i, and j are independently 0 to 5, and e and h are independently 1 to 5, a composition comprising a conjugate of any of formulae (I)-(VII) and a carrier, and a method for treating cancer in a mammal comprising administering an effective amount ofType: ApplicationFiled: September 16, 2008Publication date: March 12, 2009Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPAInventors: Zoltan Szekely, Humcha Krishnamurthy Hariprakasha, Marek W. Cholody, Christopher Michejda
-
Patent number: 7482439Abstract: Caprazene and caprazol could be synthesized by hydrolysis of a caprazamycin. There could be synthesized a caprazene-1??-amide derivative of the formula (II) and a caprazene-1??-ester derivative of the formula (III) from caprazene. Further, there could be synthesized a caprazol-1??-amide derivative of the formula (V) and a caprazol-1??-amide-3??-ester derivative and a caprazol-3??-ester derivative, etc. from caprazol. Furthermore, an imidazolidinone derivative could be synthesized from the ring-opened product of the 1,4-diazepinone ring of caprazol. The novel caprazene derivative, novel caprazol derivative and novel imidazolidinone derivative now synthesized exhibit excellent antibacterial activities against a variety of bacteria, including acid-fast bacteria.Type: GrantFiled: January 30, 2004Date of Patent: January 27, 2009Assignees: Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, Meiji Seika Kaisha, Ltd.Inventors: Toshiaki Miyake, Masayuki Igarashi, Tetsuo Shitara, Yoshiaki Takahashi, Masa Hamada
-
Publication number: 20090023665Abstract: The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes.Type: ApplicationFiled: June 26, 2008Publication date: January 22, 2009Applicant: Vicuron Pharmaceuticals Inc.Inventors: Enrico Selva, Flavia Marinelli, Daniele Losi, Linda Cavaletti, Ameriga Lazzarini, Alessandra Marazzi
-
Publication number: 20080300199Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.Type: ApplicationFiled: April 10, 2008Publication date: December 4, 2008Applicant: Achaogen Inc.Inventors: Martin Linsell, Adam Aaron Goldblum, James Aggen, Heinz Ernst Moser, Stephen Hanessian, Kandasamy Pachamuthu, Ellen Klegraf
-
Patent number: 7449181Abstract: A medicament for treating cancer for use in combination therapy with an anti-HER2 antibody, which comprises amrubicin or a pharmaceutically acceptable salt thereof as an active ingredient.Type: GrantFiled: July 26, 2001Date of Patent: November 11, 2008Assignee: Sumitomo Pharmaceuticals Company LimitedInventors: Toshihiro Noguchi, Akemi Baba, Mitsuharu Hanada
-
Publication number: 20080227963Abstract: Disclosed are processes for preparing glycopeptide phosphonate derivatives having an amino-containing side chain. Several of the process steps are conducted in a single reaction vessel without isolation of intermediate reaction products, thereby generating less waste and improving the overall efficiency and yield of the process.Type: ApplicationFiled: October 24, 2007Publication date: September 18, 2008Inventors: Michael R. Leadbetter, Martin S. Linsell, Junning Lee, Jyanwei Liu
-
Patent number: 7417129Abstract: A monosaccharide compound of formula I as shown in the specification. Processes for the preparation of the compound of formula I and methods of screening for antibacterial or antibiotic compounds involving the compound of formula I.Type: GrantFiled: April 17, 2003Date of Patent: August 26, 2008Assignee: Alchemia Pty LtdInventors: Michael Leo West, Wim Meutermans, George Adamson, Karl Schafer, Darren Schliebs
-
Patent number: 7407654Abstract: The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes.Type: GrantFiled: October 4, 2002Date of Patent: August 5, 2008Assignee: Vicuron Pharmaceuticals, Inc.Inventors: Enrico Selva, Flavia Marinelli, Daniele Losi, Linda Cavaletti, Ameriga Lazzarini, Alessandra Marazzi
-
Patent number: 7375088Abstract: This invention relates to a new class of polyene polyketides, their pharmaceutically acceptable salts and derivatives, and to methods for obtaining the compounds. One method of obtaining these compounds is by cultivation of novel strains of Streptomyces aizunensis; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to the novel strains of Streptomyces aizunensis used to produce these compounds, to the use of these compounds and their pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of fungal cell growth and cancer cell growth. The invention also relates to pharmaceutical compositions comprising these novel polyketides or a pharmaceutically acceptable salts or derivatives thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of these novel polyketides.Type: GrantFiled: January 21, 2004Date of Patent: May 20, 2008Assignee: Thallion Pharmaceuticals Inc.Inventors: Brian O. Bachmann, James B. McAlpine, Emmanuel Zazopoulos, Chris M. Farnet
-
Patent number: 7371733Abstract: The invention relates to novel paranmycin compounds that have activity against gram positive and gram negative bacteria, preferably bacteria that are resistant to other antibiotics.Type: GrantFiled: March 20, 2006Date of Patent: May 13, 2008Assignee: Utah State UniversityInventor: Cheng-Wei Tom Chang
-
Patent number: 7368431Abstract: The inventive polypeptide is embodied in the form of a similar fragment of the epidermal growth factor of aminoacid ranging from 21 to 31 and capable of efficiently binding with the receptor of the epidermal growth factor as a vector for the directed supply of anticancer agent to tumour cells. The inventive conjugate of said polypeptide contains doxorubicine and has a selective action on cancer tumours and can substantially reduce the resistance of tumour cells with respect to the anticancer agents, the conjugated parts of said agents being binded with the aid of a chemical bond which is unstable in relation to acid hydrolysis. The inventive pharmaceutical composition comprises an efficient quantity of conjugate and a carrier which is fit for intravenous injection. Said invention can be used for medicine for treating cancer patients.Type: GrantFiled: June 21, 2004Date of Patent: May 6, 2008Assignee: Zakrytoe Aktsionernoe Obschestvo “Russkie Biotechnologll”Inventors: Evgeniy Sergeevich Severin, Sergey Evgenyevich Severin, Sergey Viktorovich Lutsenko, Sergey Michaylovich Kiselev, Natalya Borisovna Feldman
-
Patent number: 7358232Abstract: The invention relates to a method for the antibiotic coating of bodies with interconnecting microcavities as well as bodies coated this way and their usage.Type: GrantFiled: June 19, 2002Date of Patent: April 15, 2008Assignee: Heraeus Kulzer GmbH & Co.KGInventors: Sebastian Vogt, Matthias Schnabelrauch, Klaus-Dieter Kühn
-
Patent number: 7259141Abstract: The present invention provides vancomycin analogs and methods related to synthesis of these analogs via chemoenzymatic techniques.Type: GrantFiled: May 19, 2005Date of Patent: August 21, 2007Assignee: Wisconsin Alumni Research FoundationInventor: Jon S. Thorson
-
Patent number: 7244712Abstract: The present invention relates to aminoglycoside compounds having antibiotic activity. Moreover, the present invention relates to L-aminoglycoside compounds and diastereomers thereof which posses antibiotic activity and are not susceptible to development of resistant bacterial strains. The present invention also relates to methods of treatment and pharmaceutical compositions that utilize or comprise one or more of aminoglycoside compounds provided by the invention.Type: GrantFiled: September 14, 2004Date of Patent: July 17, 2007Assignee: President and Fellows of Harvard CollegeInventor: Robert R. Rando
-
Patent number: 7241595Abstract: The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers.Type: GrantFiled: April 24, 2002Date of Patent: July 10, 2007Assignee: sanofi-aventis Pharma Deutschland GmbHInventors: Cenek Kolar, Jörg Czech, Klaus Bosslet, Gerhard Seemann, Hans-Harald Sedlacek
-
Patent number: 7220727Abstract: The present invention provides aminoglycosides and pharmaceutical compositions that include the aminoglycosides. The aminogylcosides are useful to treat or prevent infectious diseases (e.g., bacterial infections) in a mammal (e.g., human).Type: GrantFiled: November 1, 2001Date of Patent: May 22, 2007Assignee: Wayne State UniversityInventors: Jalal Haddad, Lakshmi Kotra, Shahriar Mobashery
-
Patent number: 7166270Abstract: Screening procedures are disclosed for identifying compounds useful for inhibiting infection or pathogenicity. Methods are also disclosed for identifying pathogenic virulence factors.Type: GrantFiled: November 3, 1997Date of Patent: January 23, 2007Assignees: The Netherlands Cancer Institute, The General Hospital CorporationInventors: Frederick M. Ausubel, Laurence G. Rahme, Man-Wah Tan, Gary B. Ruvkun, Shalina Mahajan-Miklos, Annegien Broeks, Ronald H. A. Plasterk, Georg Jander, Jacqueline Heard